The Cleveland Clinic's CEO said Friday that the top-rated U.S. hospital will work to verify technology developed by blood-testing start-up Theranos, which has recently faced allegations its devices are inaccurate.
"Everybody is skeptical about something that is disruptive in a new industry, and I think that's perfectly reasonable that they should be," Dr. Toby Cosgrove told CNBC's "Squawk Box." "I think that we need to have that verification done externally by a third party and we'd like to do that.
In March, the Cleveland Clinic announced a strategic alliance with Theranos to "enhance clinical quality, improve turnaround times, reduce the cost of care and increase patient satisfaction" through the start-up's technology.
Theranos claims its proprietary Edison machine is able to perform a range of sophisticated tests at low cost with just a few drops of blood.
Earlier this month, The Wall Street Journal cited a former Theranos employee who said just 15 of the 240 tests offered by the company were conducted on Edison machines, with the rest performed on traditional lab equipment. The "company says it abides by all applicable federal lab regulations and hasn't exaggerated its achievements. It disputes that its device could do just 15 tests," according to the Journal article.
Cosgrove said the Cleveland Clinic does not yet have Theranos technology on-site, but it is looking forward to performing a peer review.
Theranos has attracted skepticism in part because founder Elizabeth Holmes decided to have the Food and Drug Administration review the quality of its results rather than the taking the traditional approach of independent peer review.
"That has been a slower process, and this is one of the reasons why I think the scientific community has been questioning what is the capability," of the machines, he said.